Fraxinellone Inhibited Immune Evasion and Cell Growth by Inactivating HIF‐1α/STAT3/PD‐L1 Signaling in Esophageal Squamous Cell Carcinoma
Journal of Biochemical and Molecular Toxicology · 2026
DOI: 10.1002/jbt.70732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Qian Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Zhang Zhongjing College of Chinese Medicine, Nanyang Institute of Technology, Nanyang, Henan, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Hypoxia-Inducible Factor 1, alpha Subunit, Signal Transduction, Esophageal Neoplasms. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Natural Science Foundation of Henan, Nanyang Basic and Frontier Research Project.
Abstract (Originalsprache)
Esophageal squamous cell carcinoma (ESCC), the predominant histological subtype constituting approximately 80% of all esophageal malignancies worldwide, represents a significant global disease burden with distinct geographical predilection. Fraxinellone (FRA) was reported to function as a tumor suppressor in several tumors, while the role of FRA in ESCC remains unclear. In the present study, we found that FRA treatment significantly inhibited cell proliferation and colony formation of ESCC cells. On the contrary, FRA treatment promoted cell apoptosis of ESCC cells by downregulating Bcl‐2 protein and upregulating Bax and C‐caspase3 proteins. Besides, FRA pretreatment suppressed proliferation and viability of CD8 + T cells but facilitated cell apoptosis in co‐culturing system. Moreover, FRA pretreatment restrained immune evasion by attenuating CD8 + T cell activation. Mechanistically, FRA effectively inactivated HIF‐1α/STAT3/PD‐L1 signaling in ESCC cells and xenograft tumors. Ultimately, FRA treatment inhibited tumor growth in vivo. In conclusions, FRA inhibited ESCC cell growth and immune evasion by inactivating HIF‐1α/STAT3/PD‐L1 signaling in vitro and vivo. This study suggested that FRA may serve as a potential therapeutic agent for ESCC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhang Zhongjing College of Chinese Medicine, Nanyang Institute of Technology, Nanyang, Henan, China.
- Henan Key Laboratory of Zhang Zhongjing Formulae and Herbs for Immunoregulation, Nanyang Institute of Technology, Nanyang, Henan, China.
- Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
ORCID-Profile: Kai Li
Förderung
- Natural Science Foundation of Henan
- Nanyang Basic and Frontier Research Project
Zitieren
APA
Wang, Q., Bian, B., Zhang, L., Duan, P., Bian, H., Zhang, G., & Li, K. (2026). Fraxinellone Inhibited Immune Evasion and Cell Growth by Inactivating HIF‐1α/STAT3/PD‐L1 Signaling in Esophageal Squamous Cell Carcinoma. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70732
Vancouver
Wang Q, Bian B, Zhang L, Duan P, Bian H, Zhang G, et al. Fraxinellone Inhibited Immune Evasion and Cell Growth by Inactivating HIF‐1α/STAT3/PD‐L1 Signaling in Esophageal Squamous Cell Carcinoma. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.70732
BibTeX
@article{Wang2026,
author = {Wang, Qian and Bian, Bo and Zhang, Lifang and Duan, Peipei and Bian, Hua and Zhang, Guangji and Li, Kai},
title = {Fraxinellone Inhibited Immune Evasion and Cell Growth by Inactivating HIF‐1α/STAT3/PD‐L1 Signaling in Esophageal Squamous Cell Carcinoma},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
doi = {10.1002/jbt.70732}
}
EUVIMED